Abstract: The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.

Abstract: A genetic motif is extracted from at least one piece of input gene arrangement information, and based on the extracted motif, gene arrangement information including the motif as a part thereof is retrieved from previously gene information. The gene arrangement information as retrieved is added to the input gene arrangement information, to thereby improve a genetic motif extracting efficiency.

Abstract: The present invention features a method for isolating and purifying proteins and peptides of interest from a plant host, which is applicable on a larger scale. Moreover, the present invention provides a more efficient method for isolating proteins and peptides of interest than those methods described in the prior art. In general, the present method of isolating proteins and peptides of interest comprises the steps of homogenizing a plant to produce a green juice, adjusting the pH of and heating the green juice, separating the target protein/peptide from other components of the green juice by one or more cycles of centrifugation and/or resuspension, and finally purifying proteins and peptides by such procedures as chromatography and/or salt precipitation.

Abstract: A reagent for determining prothrombin time (PT) including a recombinant protein tissue factor, a mixture of synthetic phospholipids, and a beta, gamma, or delta amino acid stabilizing compound is described for monitoring extrinsic blood coagulation activities. The source for the recombinant protein tissue factor is rabbit brain, and the phospholipids employed are palmitoyloleoylphosphatidylcholine (POPC) and palmitoyloleoylphosphatidylserine (POPS). The particular formulation buffer used to dilute the lipidated tissue factor provides a reagent that is optionally dried without lyophilization and remains stable for at least about 2 weeks at 37 C as either a liquid or a dried powder. A method for preparing the improved PT reagent and a method of using the reagent to analyze blood PT is also provided.

Abstract: The present invention provides an apparatus for producing a mass-coded combinatorial library comprising a set of compounds having the general formula X(Y)n, where X is a scaffold, each Y is, independently, a peripheral moiety, and n is an integer greater than 1. The apparatus comprises a digital processor assembly for selecting a peripheral moiety precursor subset from a peripheral moiety precursor set. The subset includes a sufficient number of peripheral moiety precursors that at least about 50 distinct combinations of n peripheral moieties derived from the peripheral moiety precursors in the subset exist. The subset of peripheral moiety precursors is selected so that at least about 90% of all possible combinations of n peripheral moieties derived from the subset have a molecular mass sum which is distinct from the molecular mass sums of all of the other combinations of n peripheral moieties. Methods of use of the mass-coded combinatorial library produced by this apparatus are also disclosed.

Abstract: A composition for inhibiting an increase in, or lowering, a blood sugar level, which comprises, as a main component, a concentrate of a hot water or alcohol extract of leaves of Lagerstroemia speciosa, Linn. or Pers. and has an corosolic acid content of 0.01 to 15 mg per 100 mg of the concentrate, and a method of inhibiting an increase in, or lowering, a blood sugar level by oral administration of the composition.

Abstract: The present invention provides methods and systems for assembling a genome from a shot-gun set of end sequenced DNA fragments. Specifically, the present invention provides a method of determining the genomic sequence (base sequence and orientation) of a complex genome using DNA sequence information generated from a collection of DNA fragments obtained from the genome. The present method is particularly useful in assembling genomes of at least 10 MB (up to 5 GB) and which are made up of at least 5% repetitive DNA sequences (up to 25% repetitive), but can be used also for smaller genomes with a lower percentage of repetitive DNA.

Abstract: The present invention provides a method for producing a mass-coded combinatorial library comprising a set of compounds having the general formula X(Y)n, where X is a scaffold, each Y is, independently, a peripheral moiety, and n is an integer greater than 1. The method comprises selecting a peripheral moiety precursor subset from a peripheral moiety precursor set. The subset includes a sufficient number of peripheral moiety precursors that at least about 50 distinct combinations of n peripheral moieties derived from the peripheral moiety precursors in the subset exist. The subset of peripheral moiety precursors is selected so that at least about 90% of all possible combinations of n peripheral moieties derived from the subset have a molecular mass sum which is distinct from the molecular mass sums of all of the other combinations of n peripheral moieties. The method further comprises contacting the peripheral moiety precursor subset with a scaffold precursor which has n reactive groups.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

Abstract: A method and apparatus for modeling cellular structure is disclosed. The system incorporates a theoretical hypotheses of cellular physiology into a simulation framework that allows direct comparison of simulation results with experimental data. The description of the biological model is kept independent of the solution by the use of an integrated anatomical and physiological modeling language. This framework allows complex heterogeneous intracellular chemical simulations to be built with little or no knowledge of the underlying numerical methods. Because the simulation results are easily compared to the experimental results, the user can more easily confirm the hypothesis.

Abstract: The present invention provides a method for producing a mass-coded combinatorial library comprising a set of compounds having the general formula X(Y)n, where X is a scaffold, each Y is, independently, a peripheral moiety, and n is an integer greater than 1. The method comprises selecting a peripheral moiety precursor subset from a peripheral moiety precursor set. The subset includes a sufficient number of peripheral moiety precursors that at least about 50 distinct combinations of n peripheral moieties derived from the peripheral moiety precursors in the subset exist. The subset of peripheral moiety precursors is selected so that at least about 90% of all possible combinations of n peripheral moieties derived from the subset have a molecular mass sum which is distinct from the molecular mass sums of all of the other combinations of n peripheral moieties. The method further comprises contacting the peripheral moiety precursor subset with a scaffold precursor which has n reactive groups.

Abstract: A computer based technique for the global investigation of property spaces is described. More particularly, a technique is described for the global investigation of chemical space, with reference to drugs, using a system comprised of molecules and descriptors that allows systematic mapping of the chemical space. The technique is used to generate a map of N-dimensional chemical space that allows one to examine, in a consistent manner with existing tools, the inner relationship between various molecules. The technique therefore allows one to investigate unexplored regions of the chemical space, avoiding redundancy, generating compounds with similar chemical information content, or to focus on subsets of the chemical space that are relevant to drug-like structures, without additional errors due to extrapolation.

Abstract: In this invention, a measurement of cell permeability is determined by obtaining a measure of the volume of fluid which crosses a sample cell membrane in response to an altered environment. A lytic agent may be used to drive fluid across the cell membranes and thereby cause a change in cell volume. An alteration in osmolality of a sample suspension is preferred, in which the sample suspension is subjected to a continuous osmotic gradient.

Abstract: The present invention relates to methods for enhancing gastrointestinal motility. In particular, the invention relates to the use of neurotrophin-3 and its analogues for enhancing gastrointestinal motility. Methods of using neurotrophin-3 and its analogues for treating gastrointestinal hypomotility disorders are also provided.

Abstract: The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absorption of an administered compound of interest. The methods utilize the tool, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver. The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data.

Abstract: The present invention is directed to the use of computational and other experimental data in the design of new pharmaceuticals, and in predicting the metabolism and toxicological profiles thereof. Computational and other information is used to further understand drug metabolism and toxicology, particulary in relation to monooxygenase enzymes, such as those of the CYP system, that are involved in drug metabolism. Information derived according to the practice of the invention is useful in determining the clearance or half-life of drugs, and the nature and toxicity of byproducts resulting from their metabolism. The invention provides novel and powerful new approaches to drug design.

Abstract: The sequences of 5′ ESTs and consensus contigated 5′ ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5′ ESTs and consensus contigated 5′ ESTs may be used to obtain cDNAs and genomic DNAs corresponding to the 5′ ESTs and consensus contigated 5′ ESTs. The 5′ ESTs and consensus contigated 5′ ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5′ ESTs and consensus contigated ESTs. The 5′ ESTs and consensus contigated 5′ ESTs may also be used to design expression vectors and secretion vectors.

Abstract: The present application relates to nucleic acids and polypeptides from Cenarchaeum symbiosum. Methods of making the polypeptides and antibodies against the polypeptides are also described.

Abstract: The invention provides neuropeptide ligands, G protein-coupled receptors and methods of screening for modulators of receptor activity. Identified modulators, including neuropeptide ligand mimetics, are useful as biostatic and biocidal agents of varying scope, ranging from lethal activity restricted to particular invertebrate parasites to broad spectrum invertebrate parasiticides active on a wide range of invertebrates, including helminths and insects.

Abstract: Compounds of the formula wherein the compound is neopentylene 1-phenylvinylphosphonate.